Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
PT-141 (Bremelanotide) Melanocortin-4 receptor agonist. Activates hypothalamic desire circuits independent of hormone levels 30–45 minutes subcutaneous FDA-approved for HSDD based on Phase 3 RCTs (n=1,267). Strongest human eviden…
N-Acetylcysteine (NAC) Increases intracellular glutathione synthesis by providing rate-limiting cysteine substrate Oral. Absorbed intact, crosses BBB 600–1200mg twice daily Mercury, lead, cadmium (via GSH conjugation) Gold standa…
Fat Loss Priority Tirzepatide 10–15mg/wk + Tesofensine 0.25–0.5mg/day GLP-1/GIP appetite suppression + monoamine reuptake thermogenesis 12–18% body fat reduction, 20–25% lean mass loss of total weight Weekly (tirzepatide) + daily…
Before selecting a peptide, understand that purity, peptide sequence accuracy, and reconstitution stability determine whether the compound delivers its intended biological effect. Or degrades into inactive fragments before it rea…
Thymosin Alpha-1 (Thymalin) Immune modulation; reduces inflammatory cytokines (IL-6, TNF-alpha) that inhibit epithelial repair Not typically used topically 0.5–2.0 mg subcutaneous, twice weekly 4–6 weeks Best for cases where chro…
BPC-157 VEGF upregulation, NO pathway modulation, collagen organization 200–500 mcg daily (animal models) Freezing phase (weeks 0–12) 2–8°C refrigerated, 28-day stability post-reconstitution Strongest evidence for early inflammat…
Ipamorelin Stimulates pituitary GH release via ghrelin receptor activation without cortisol spike 200–300mcg 2–3× daily ~2 hours Fasted state (3+ hours post-meal) Best for gradual energy improvement over weeks. Not immediate effe…
Epithalamin Pineal extract; TERT upregulation 33.4% telomere length increase in elderly patients (12 months) Limited Russian trials; no large Western RCTs Research use only; not commercially available Strongest published human da…
Dihexa HGF mimetic; c-Met receptor activation → synaptogenesis 0.1–2 mg/kg (subcutaneous or oral) Oral: 50–60%; Subcutaneous: ~100% 28 days at 2–8°C Highest potency-per-dose; oral administration viable; limited human safety data …
Cerebrolysin BDNF/GDNF upregulation in dopaminergic neurons High (mixture of low-MW neuropeptides) 30mL IV infusion, 5×/week for 4 weeks Multiple Phase III trials, meta-analysis published Strongest clinical evidence for adjunct n…
GLP-1 Agonists (Semaglutide, Tirzepatide) Insulin sensitisation, reduced hepatic glucose output, slowed gastric emptying 30–40% hepatic fat reduction, 59% NASH resolution in NEJM trial 2.4mg weekly (semaglutide), 10–15mg weekly (…
Thymosin Alpha-1 TLR activation on dendritic cells, shifts cytokine profile toward IL-10, enhances thymic T-cell output 1.6–3.2mg subcutaneous Twice weekly 12–16 weeks First-line choice for immune reconstitution in PTLDS. Address…
Mechanism Linear MC1R agonist. Selective binding to melanocortin-1 receptor only Cyclic peptide. Binds MC1R, MC3R, MC4R (broader receptor activation) UV-induced DNA damage triggers p53-mediated melanogenesis MT-I is more selectiv…
DSIP (Delta Sleep-Inducing Peptide) Modulates delta-wave activity through GABAergic signaling and stress hormone suppression 100–500mcg subcutaneous 30–45 minutes before bed Increases slow-wave sleep duration by 15–25%; reduces s…
Cerebrolysin Neurotrophic factor cocktail (NGF, BDNF, GDNF) Multi-pathway neuroprotection 10–30 mL IV, 5 days/week 4–12 weeks Broadest neurotrophic coverage. Supports both neuron survival and axonal regrowth Best for neurodegener…
BPC-157 VEGF modulation, nitric oxide signaling, tight junction protein synthesis Gut barrier restoration, reduced intestinal permeability, decreased systemic LPS translocation 250–500 mcg SC twice daily 4–8 weeks for barrier mar…
| Peptide | Primary Mechanism | Sleep Phase Affected | Research Maturity | Typical Dosing Range (Research Models) | Reconstitution Stability | Bottom Line ||—|—|—|—|—|—|| DSIP | Delta-opioid receptor agonism | Slow-wave (NREM Sta…
CJC-1295 with DAC GHRH analogue. Stimulates pituitary GH synthesis and release, extended half-life 38–50% (monotherapy) Once or twice weekly (subcutaneous) Requires combination with GHRP for optimal effect Most reliable long-term…
BPC-157 VEGFR-2 upregulation drives angiogenesis; fibroblast migration acceleration 200–500 mcg daily SC, near injury site Animal models + case reports; no RCTs Requires daily dosing; local administration preferred TB-500 Actin p…
Thymalin Thymic T-cell maturation, IL-2 upregulation Th2 immune skewing, lymphopenia 10–20mg IM every 3–5 days Animal + human observational Strongest immune restoration data. No Lyme-specific trials Cerebrolysin Neurotrophic fact…